ASH 2018: New Advances in CAR T Studies with Damian Green, MD
At the recent American Society of Hematology meeting (ASH), Dr. Damian Green joined the Myeloma Crowd to share two CAR T studies he is working on.
He shared data on the Juno/Celgene study that showed rapid and good responses for patients with an average 11 lines of prior therapy for a BCMA targeted CAR T treatment. The CAR T space is getting crowded and it is unknown at this point whose CAR T therapy will offer the longest and deepest remissions.
Evan at the lowest CAR T doses, Dr. Green noted that the responses were fast and deep, suggesting that some CAR T therapies may be better than others.
Patients who joined the study were broken into two groups:
Group 1 included patients with 10-30% of myeloma cells in their bone marrow. Group 2 included patients with more than 30% of myeloma cells in their bone marrow.
Patients had CD8+ and CD4+ cells drawn out, which were then engineered to target BCMA. A growth factor receptor (EGFRt) was added. The patients received chemotherapy prior to the administration of the CAR T.
Seven patients so far have received treatment. The median percentage of myeloma cells in the bone marrow at time of study enrollment was 58%. All patients had at least one high risk feature, most (71%) had received prior autologous stem cell transplant and 43% had received a prior allogeneic (donor) transplant. One patient had plasma cell leukemia.
Within 28 days of treatment, all patients' monoclonal protein was decreased by an average of 73%. At 90 days, the BCMA CAR T could still be detected in patients. Learn more about this study here:
Immunotherapy with CAR T Trial
- Patients who have received a prior allogeneic (donor) transplant. This is unheard of, as most clinical trials exclude these patients.
- Patients who have received any prior CAR T therapy (also unheard of)
- Patients receiving any prior BCMA targeted treatment